CymaBay Therapeutics Inc.

CymaBay Therapeutics focuses on liver and chronic diseases. Lead product candidate seladelpar treats primary biliary cholangitis (PBC). Developing MBX-2982 for type 1 diabetes. Licensed to develop seladelpar for PBC from ABW Cyclops SPV LP. Formally known as Metabolex, Inc. Headquartered in Fremont, California. Subsidiary of Gilead Sciences since March 22, 2024.

Overview

Sector

Target Price

0.2 USD

Current Price

- USD

Potential

-99%

Strengths

EV/EBITDA (-42.41) is lower than the sector mean (85.60).
EV/EBIT (-42.07) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -99.38%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company have lower returns than the sector in which it operates. ROIC (-17.83%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	-42.4
Price/Free Cash Flow'	100.0
ROIC	-17.8%
Net Debt/EBITDA	1.1